Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

April 6, 2023

https://www.globenewswire.com/news-release/2023/04/06/2642971/0/en/Foghorn-Therapeutics-to-Highlight-Transcription-Factor-and-Protein-Degradation-Capabilities-at-the-18th-Annual-Drug-Discovery-Chemistry-Meeting.html

CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced upcoming oral presentations highlighting its transcription factor and protein degradation capabilities at the 18th Annual Drug Discovery Chemistry Meeting. The hybrid meeting will be held April 10–13, 2023, at the Hilton Bayfront in San Diego, CA, and virtually.

Read more at globenewswire.com

Related news for (FHTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.